Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

REGNING: RWE Retrospektiv studie for å evaluere Cenobamate Impact on Health Care Resource Utilization

Retrospektiv evaluering av Cenobamates utnyttelse

The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Faktiske)

117

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Netherlands
      • Heeze, Netherlands, Nederland
        • Kempenhaeghe - Academisch Centrum voor Epilepsie
    • Spain
      • Barcelona, Spain, Spania
        • Epilepsy Unit - Neurology Department Valle de Hebron Hospital
      • Madrid, Spain, Spania
        • Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
      • Valencia, Spain, Spania
        • Consorcio Hosp. General Universitario Valencia
    • UK
      • Glasgow, UK, Storbritannia
        • Institute of Neurosciences NHS Greater Glasgow and Clyde
      • Wolverhampton, UK, Storbritannia
        • Epilepsies - The Royal Wolverhampton NHS Trust
    • Switzerland
      • Zurich, Switzerland, Sveits
        • Department of Neurology, University Hospital Zurich
    • Germany
      • Freiburg im Breisgau, Germany, Tyskland
        • Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
      • Hamburg, Germany, Tyskland
        • Epileptologicum
      • Kork, Germany, Tyskland
        • Diakonie Kork, Epilepsiezentrum

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.

Beskrivelse

Inclusion Criteria:

  1. Male and female patients of any ethnic origin ≥18 years old at index date;
  2. Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
  3. Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
  4. Patients with at least 6 months of data coverage in the medical records prior to the index date;
  5. Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
  6. Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.

Exclusion Criteria:

  1. Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
  2. Patients who started cenobamate within an EAP;
  3. Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
  4. Patients with specific syndrome (e.g. LGS and Dravet);
  5. Pregnancy or lactation;
  6. Patients without self-judgement ability;
  7. Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
  8. Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Adult patients affected by epilepsy with focal-onset seizures

Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits;

0-12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
Tidsramme: 0-12 months

To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected;

0-12 months
Effectiveness of cenobamate used as adjunctive therapy
Tidsramme: 0-12 months

To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days);

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
Tidsramme: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:

  • the number of epilepsy-related surgery (how many patients initiated cenobamate while they were in waiting list or post-surgical intervention, i.e. surgical failure);
  • the number of hospitalizations due to surgery related to epilepsy (e.g. fractures due to falls);
  • the number of Intensive Care Unit (ICU) visits;
0-12 months
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
Tidsramme: 0-12 months

To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:

  • Number and length of hospitalizations of all-cause inpatient visits,
  • Number of ER visits,
  • Number of outpatient visits. All-cause HCRU will be defined as HCRU due to any cause;
0-12 months
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
Tidsramme: 0-12 months

To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected.

0-12 months
Safety of cenobamate used as adjunctive therapy
Tidsramme: 0-12 months

To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study.

0-12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. desember 2024

Primær fullføring (Faktiske)

30. desember 2025

Studiet fullført (Faktiske)

30. oktober 2026

Datoer for studieregistrering

Først innsendt

1. april 2025

Først innsendt som oppfylte QC-kriteriene

9. april 2025

Først lagt ut (Faktiske)

10. april 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 169(A)AV23432

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere